According to receptor subtypes, the patients were classified into HR (hormone receptor)+HER2-, HER2+ and TNBC (triple negative breast cancer) subtypes, and we found that PIV was significantly elevated in IBC cases in all pathological types (Figure 2C). The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.